|
1.
|
H OhgakiP DessenB JourdeGenetic pathways
to glioblastoma: a population-based studyCancer
Res6468926899200410.1158/0008-5472.CAN-04-133715466178
|
|
2.
|
R StuppWP MasonMJ van den BentRadiotherapy
plus concomitant and adjuvant temozolomide for glioblastomaN Engl J
Med352987996200510.1056/NEJMoa04333015758009
|
|
3.
|
DN LouisH OhgakiOD WiestlerThe 2007 WHO
classification of tumors of the central nervous systemActa
Neuropathol11497109200710.1007/s00401-007-0243-417618441
|
|
4.
|
CBTRUSStatistical report: primary brain
tumors in the United States, 2000–2004Central brain tumor registry
of the United StatesChicago2008
|
|
5.
|
J ClarkeN ButowskiSR ChangRecent advances
in therapy for glioblastomaArch
Neurol67279283201010.1001/archneurol.2010.5
|
|
6.
|
M SchmidingerL LinzmayerA
BechererPsychometric-and quality-of-life assessment in long-term
glioblastoma survivorsJ
Neurooncol635561200310.1023/A:102374030316212814255
|
|
7.
|
The Cancer Genome Atlas (TCGA) Research
NetworkComprehensive genomic characterization defines human
glioblastoma genes and core
pathwaysNature45510611068200810.1038/nature0738518772890
|
|
8.
|
A Von DeimlingDN LouisOD WiestlerMolecular
pathways in the formation of gliomasGlia1532833819958586467
|
|
9.
|
K WatanabeO TachibanaK SataY YonekawaP
KleihuesH OhgakiOverexpression of the EGF receptor and p53
mutations are mutually exclusive in the evolution of primary and
secondary glioblastomasBrain
Pathol6217223199610.1111/j.1750-3639.1996.tb00848.x8864278
|
|
10.
|
PA SteckH LinLA LangfordFunctional and
molecular analyses of 10q deletions in human gliomasGenes
Chromosomes
Cancer24135143199610.1002/(SICI)1098-2264(199902)24:2%3C135::AID-GCC6%3E3.0.CO;2-A9885980
|
|
11.
|
DJ BratEG van MeirVaso-occlusive and
prothrombotic mechanisms associated with tumor hypoxia, necrosis,
and accelerated growth in glioblastomaLab
Invest84397405200410.1038/labinvest.370007014990981
|
|
12.
|
H FujisawaRM ReisM NakamuraLoss of
heterozygosity on chromosome 10 is more extensive in primary (de
novo) than in secondary glioblastomasLab
Invest806572200010.1038/labinvest.378000910653004
|
|
13.
|
H NoushmehrDJ WeisenbergerK
DiefesIdentification of a CpG island methylator phenotype that
defines a distinct subgroup of gliomaCancer
Cell17510522201010.1016/j.ccr.2010.03.01720399149
|
|
14.
|
MC SchmidtS AntweilerN UrbanImpact of
genotype and morphology on the prognosis of glioblastomaJ
Neuropathol Exp Neurol61321328200211939587
|
|
15.
|
R AlbarosaBM ColomboL RozDeletion mapping
of gliomas suggest the presence of two small regions for candidate
tumor-suppressor genes in a 17-cM interval on chromosome 10qAm J
Hum Genet581260126719968651304
|
|
16.
|
DW ParsonsS JonesX ZhangAn integrated
genomic analysis of human glioblastoma
multiformeScience32118071812200810.1126/science.116438218772396
|
|
17.
|
SM LeeHJ KohDC ParkBJ SongTL HuhJW
ParkCytosolic NADP(+)-dependent isocitrate dehydrogenase status
modulates oxidative damage to cellsFree Radic Biol
Med32118511962002
|
|
18.
|
FE BleekerS LambaS LeenstraIDH1 mutations
at residue p.R132 (IDH1(R132)) occur frequently in high-grade
gliomas but not in other solid tumorsHum
Mutat30711200910.1002/humu.2093719117336
|
|
19.
|
A PeraudK WatanabeKH PlateY YonekawaP
KleihuesH Ohgakip53 mutations versus EGF receptor expression in
giant cell glioblastomasJ Neuropathol Exp
Neurol5612361241199710.1097/00005072-199711000-000089370234
|
|
20.
|
BK RasheedRE McLendonHS FriedmanChromosome
10 deletion mapping in human gliomas: a common deletion region in
10q25Oncogene102243224619957784070
|
|
21.
|
IS KilSY KimSJ LeeJW ParkSmall interfering
RNA-mediated silencing of mitochondrial NADP+-dependent
isocitrate dehydrogenase enhances the sensitivity of HeLa cells
toward tumor necrosis factor-alpha and anticancer drugsFree Radic
Biol Med4311971207200717854715
|
|
22.
|
GJ DohrmannJR FarwellJT
FlanneryGlioblastoma multiforme in childrenJ
Neurosurg44442448197610.3171/jns.1976.44.4.0442
|
|
23.
|
U SureD RüediO TachibanaDetermination of
p53 mutations, EGFR overexpression, and loss of p16 expression in
pediatric glioblastomasJ Neuropathol Exp
Neurol56782789199710.1097/00005072-199756070-000049210874
|
|
24.
|
V SuriP DasP PathakPediatric
glioblastomas: a histopathological and molecular genetic studyNeuro
Oncol11274280200910.1215/15228517-2008-09218981259
|
|
25.
|
BR RoodTJ MacDonaldPediatric high-grade
glioma: molecular genetic clues for innovative therapeutic
approachesJ
Neurooncol75267272200510.1007/s11060-005-6749-516195804
|
|
26.
|
N ShahB LinZ SibenallerComprehensive
analysis of MGMT promoter methylation: correlation with MGMT
expression and clinical response in GBMPLoS
One6e16146201110.1371/journal.pone.001614621249131
|
|
27.
|
ME HegiAC DiserensT GorliaMGMT gene
silencing and benefit from temozolomide in glioblastomaN Engl J
Med3529971003200510.1056/NEJMoa04333115758010
|
|
28.
|
K PalanichamyM ErkkinenA
ChakravartiPredictive and prognostic markers in human
glioblastomasCurr Treat Options
Oncol7490504200610.1007/s11864-006-0024-717032561
|
|
29.
|
MD PradosV LevinBiology and treatment of
malignant gliomaSemin Oncol271102000
|
|
30.
|
WA FreijeFE Castro-VargasZ FangGene
expression profiling of gliomas strongly predicts survivalCancer
Res6465036510200410.1158/0008-5472.CAN-04-045215374961
|
|
31.
|
HS PhillipsS KharbandaR ChenMolecular
subclasses of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in
neurogenesisCancer Cell9157173200610.1016/j.ccr.2006.02.019
|
|
32.
|
K WatanabeK SatoW BiernatIncidence and
timing of p53 mutations during astrocytoma progression in patients
with multiple biopsiesClin Cancer Res352353019979815715
|
|
33.
|
C AdamsonOO KanuAI MehtaGlioblastoma
multiforme: a review of where we have been and where we are
goingExpert Opin Investig
Drugs1810611083200910.1517/1354378090305276419555299
|
|
34.
|
FB FurnariT FentonRM BachooMalignant
astrocytic glioma: genetics, biology, and paths to treatmentGenes
Dev2126832710200710.1101/gad.159670717974913
|
|
35.
|
H OhgakiP KleihuesGenetic pathways to
primary and secondary glioblastomaAm J
Pathol7014451453200710.2353/ajpath.2007.070011
|
|
36.
|
EG Van MeirCG HadjipanayisAD NordenHK
ShuPY WenJJ OlsonExciting new advances in neuro-oncology: the
avenue to a cure for malignant gliomaCA Cancer J
Clin60166193201020445000
|
|
37.
|
RG VerhaakKA HoadleyE PurdomIntegrated
genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR
and NF1Cancer Cell1798110201010.1016/j.ccr.2009.12.02020129251
|
|
38.
|
SA GrossmanJF BataraCurrent management of
glioblastoma multiformeSemin
Oncol31635644200410.1053/j.seminoncol.2004.07.00515497116
|
|
39.
|
OO KanuA MehtaC DiGlioblastoma multiforme:
a review of therapeutic targetsExpert Opin Ther
Targets13701718200910.1517/1472822090294234819409033
|
|
40.
|
H OhgakiGenetic pathways to
glioblastomasNeuropathology2517200510.1111/j.1440-1789.2004.00600.x
|
|
41.
|
D KrexB KlinkC HartmannLong-term survival
with glioblastoma
multiformeBrain13025962606200710.1093/brain/awm20417785346
|
|
42.
|
D XieYX ZengHJ WangAmplification and
overexpression of epidermal growth factor receptor gene in
glioblastomas of Chinese patients correlates with patient’s age but
not with tumor’s clinicopathological pathwayActa
Neuropathol110481489200516151725
|
|
43.
|
M LacroixD Abi-SaidDR FourneyA
multivariate analysis of 416 patients with glioblastoma multiforme:
prognosis, extent of resection, and survivalJ
Neurosurg95190198200110.3171/jns.2001.95.2.019011780887
|
|
44.
|
JF MineoA BordronM BaronciniPrognosis
factors of survival time in patients with glioblastoma multiforme:
a multivariate analysis of 340 patientsActa
Neurochir149245252200710.1007/s00701-006-1092-y17273889
|
|
45.
|
M GlasC HappoldJ RiegerLong-term survival
of patients with glioblastoma treated with radiotherapy and
lomustine plus temozolomideJ Clin
Oncol2712571261200910.1200/JCO.2008.19.219519188676
|
|
46.
|
RE McLendonEC HalperinIs the long-term
survival of patients with intracranial glioblastoma multiforme
overstated?Cancer9817451748200310.1002/cncr.1166614534892
|
|
47.
|
YH LiuS SheteCJ EtzelPolymorphisms of
LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand
break repair pathway predict glioblastoma survivalJ Clin
Oncol2824672474201010.1200/JCO.2009.26.621320368557
|
|
48.
|
JP SteinbachHP BlaicherU
HerrlingerSurviving glioblastoma for more than 5 years: the
patient’s perspectiveNeurology66239242200616434662
|
|
49.
|
LM DeAngelisChemotherapy for brain
tumors-a new beginningN Engl J
Med35210361038200510.1056/NEJMe05801015758016
|
|
50.
|
MW McDermottPK SneedPH GutinInterstitial
brachytherapy for malignant brain tumorsSemin Surg
Oncol147987199810.1002/(SICI)1098-2388(199801/02)14:1%3C79::AID-SSU10%3E3.0.CO;2-49407634
|
|
51.
|
BL LiuJX ChengX ZhangWei
ZhangControversies concerning the application of brachytherapy in
central nervous system tumorsJ Cancer Res Clin
Oncol136173185201010.1007/s00432-009-0741-y19956971
|
|
52.
|
H BremS PiantadosiPC
BurgerPlacebo-controlled trial of safety and efficacy of
intraoperative controlled delivery by biodegradable polymers of
chemotherapy for recurrent gliomas. The Polymer-brain Tumor
Treatment
GroupLancet34510081012199510.1016/S0140-6736(95)90755-6
|
|
53.
|
S SathornsumeteeJN RichNew treatment
strategies for malignant gliomasExpert Rev Anticancer
Ther610871104200610.1586/14737140.6.7.1087
|
|
54.
|
AS ChiAG SorensenRK JainTT
BatchelorAngiogenesis as a therapeutic target in malignant
GliomasOncologist14621636200910.1634/theoncologist.2008-027219487335
|
|
55.
|
RK JainA new target for tumor therapyN
Engl J Med36026692671200910.1056/NEJMcibr090205419535806
|
|
56.
|
PY WenTherapy for recurrent high-grade
gliomas: does continuous dose-Intense temozolomide have a role?J
Clin Oncol2820512057201020308652
|
|
57.
|
WK YungRE AlbrightJ OlsonA phase II study
of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapseBr J
Cancer83588593200910.1054/bjoc.2000.131610944597
|
|
58.
|
A MoustakasTN KreislNew treatment options
in the management of glioblastoma multiforme: a focus on
bevacizumabOncol Targets Ther32738201020616955
|
|
59.
|
S SathornsumeteeJN RichDesigner therapies
for glioblastoma multiformeAnn NY Acad
Sci1142108132200810.1196/annals.1444.00918990124
|
|
60.
|
N LutherNK CheungEP
SouliopoulosInterstitial infusion of glioma-targeted recombinant
immunotoxin 8H9scFv-PE38Mol Cancer
Ther910391046201010.1158/1535-7163.MCT-09-099620371725
|
|
61.
|
Y IwadateT MatsutaniY HasegawaSelection of
chemotherapy for glioblastoma expressing
O6-methyltransferaseExp Ther Med15357201023136592
|
